Drug intelligence / Profile preview

ATX-03

Development stage: Unknown
Lead developer: ARTHEx Biotech
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

ATX-03 is an investigational antisense oligonucleotide being developed by ARTHEx Biotech SL. It is currently in the discovery phase, with its primary therapeutic area identified as neoplasms (cancer). The drug is designed to act by targeting a specific microRNA, aiming to modulate gene expression and interfere with disease pathogenesis. However, the precise microRNA target and the detailed functional effects of ATX-03 are not yet publicly disclosed.

Beyond the preview

Go deeper on ATX-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX-03.

Explore the full profile